IMUX

Immunic (IMUX)

About Immunic (IMUX)

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company is headquartered in New York, NY.

Details

Daily high

$1.10

Daily low

$1.00

Price at open

$1.04

52 Week High

$2.11

52 Week Low

$0.97

Market cap

90.1M

Dividend yield

0.00%

Volume

1.3M

Avg. volume

857,392

P/E ratio

-.81

Immunic News